Atreca, Inc. BCEL
Set alert
As of Jun 14, 3:28 PM ET
52-week range unavailable
- Open
- 0.0912
- Prev close
- 0.09
- Mkt cap
- 3.12M
- Vol
- 122.11K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.09
- High
- 0.0931
- Forward P/E
- -0.09
- Beta
- 1.09
- Short ratio
- 0.16
- Inst. own
- 24.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jun 19, 2024
- 50-d avg
- 0.18102
- 200-d avg
- 0.34927
- 1y target
- 5.50
Discussion (14)
Sign in to join the discussion
VICKY HANUKA BCEL 3 years ago #6Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi
-- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.
VICKY HANUKA BCEL 3 years ago #8Merge is happening October 9 don’t miss it
Stevostock BCEL 4 years ago #9Added 300 Fuk the shorts
Stevostock BCEL 4 years ago #10Don’t let the shorts steal your shares